Antiepileptic drugs and puberty.
This paper investigates pubertal development in 57 epileptic subjects, ranging in age from 6 to 15 years, under anti-epileptic therapy for at least 2 years. The results were compared with those from a control group of healthy volunteers. The onset of stage II puberty was significantly earlier in both male and female treated epileptics than in healthy control subjects: at this stage serum levels of 17-beta-estradiol (E2) were found to be significantly lower in treated epileptic females than in healthy control females and the serum levels of follicle-stimulating hormone (FSH) significantly lower in treated epileptic males than in control subjects. At stage III puberty, serum levels of FSH were significantly lower both in male and female treated epileptic than in healthy control subjects.
D000293:Adolescent; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000494:pharmacology*; D002220:Carbamazepine / Q000494:pharmacology; D002648:Child; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010634:Phenobarbital / Q000494:pharmacology; D011627:Puberty / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D014635:Valproic Acid / Q000494:pharmacology
D000927:Anticonvulsants; D002220:Carbamazepine; D013739:Testosterone; D004958:Estradiol; D014635:Valproic Acid; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D010634:Phenobarbital